Active substance
Results for the substance apixaban
20 results shown
About this active substance
Apixaban is an oral anticoagulant from the class of direct factor Xa inhibitors, used for the prevention and treatment of thromboembolic disorders. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.
Apixaban works by inhibiting factor Xa, an essential enzyme in the coagulation process, thereby reducing the formation of blood clots. Unlike traditional anticoagulants such as warfarin, apixaban does not require regular INR (prothrombin time) monitoring and has fewer drug interactions.
Common side effects include minor bleeding, such as nosebleeds (epistaxis) or bruising. In rare cases, severe bleeding, such as gastrointestinal or intracranial hemorrhage, may occur. Patients should inform their doctor about any signs of unusual bleeding.
Apixaban should be used with caution in patients with severe renal impairment, liver disease, or an increased risk of bleeding. It is contraindicated in patients with active bleeding or those undergoing treatments that significantly increase the risk of hemorrhage.
-
-
ELIQUIS 2.5mg film-coated tablets BRISTOL MYERS SQUIBB ORIGINAL MEDICINE
-
VENIXAN 2.5mg film-coated tablets REMEDICA
-
VENIXAN 5mg film-coated tablets REMEDICA
-
XALPEBON 2.5mg film-coated tablets MEDOCHEMIE
-
XALPEBON 5mg film-coated tablets MEDOCHEMIE
-
APIXABAN ACCORD 2.5mg film-coated tablets
-
APIXABAN ACCORD 5mg film-coated tablets
-
APIXABAN GEMAX PHARMA 2.5mg film-coated tablets
-
APIXABAN GEMAX PHARMA 5mg film-coated tablets
-
APIXABAN IASIS 1.25mg/ml oral suspension IASIS PHARMACEUTICAL
-
BIFIZED 2.5mg film-coated tablets IASIS PHARMACEUTICAL
-
BIFIZED 5mg film-coated tablets IASIS PHARMACEUTICAL
-
APIXABAN TERAPIA 2.5mg film-coated tablets
-
APIXABAN TERAPIA 5mg film-coated tablets
-
APIXABAN PHARMAZAC 2.5mg film-coated tablets
-
APIXABAN PHARMAZAC 5mg film-coated tablets
-
APIXABAN BIOEEL 2.5mg film-coated tablets
-
APIXABAN BIOEEL 5mg film-coated tablets
-
APIXABAN SLAVIA 2.5mg film-coated tablets SLAVIA PHARM